CompletedPhase 4

Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)

France50 participantsStarted 2014-04

Plain-language summary

Numerous trials support the efficacy and safety of volatile anesthetic agents, namely inhalation of sevoflurane through dedicated devices, for the sedation of ICU patients. Several preclinical studies have shown that sevoflurane inhalation improves gas exchange and decreases pulmonary and systemic inflammation in experimental models of acute respiratory distress syndrome (ARDS). The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of an early 48-hour sevoflurane inhalation on gas exchange and inflammation in patients with ARDS.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with criteria for moderate to severe ARDS since less than 24 hours ( * Informed consent Exclusion Criteria: * Suspected or proven intracranial hypertension * Midazolam, sevoflurane or cisatracurium allergy * Medical history of malignant hyperthermia * Severe liver failure * Chemotherapy treatment in the last month * Severe neutropenia (\< 0.5 G/l)

What they're measuring

PaO2/FiO2 ratio

Timeframe: at 48 hours

Trial details

NCT IDNCT02166853

SponsorUniversity Hospital, Clermont-Ferrand

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-02

View on ClinicalTrials.gov More Acute Respiratory Distress Syndrome trials